Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT02668549Completed

Cross-Sectional Study to Define and Validate "Doctor/Pharmacy Shopping" as Outcomes Suggestive of Abuse and/or Addiction

Role: collaborator

NCT02823535Not ApplicableCompleted

Iwin: Individual Well-Being Navigator

Role: collaborator

NCT03028207Completed

A Cross-sectional Study on COPD Prevalence

Role: collaborator

NCT02488421Completed

Real Evidence of Anticoagulation Treatment in Non-valvular Atrial Fibrillation in Germany, UK and France: REACT-AF2

Role: collaborator

NCT02427516Completed

Cost of Monitoring Patients Treated With Vitamin K Antagonists in Spain

Role: collaborator

NCT01076192Completed

Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE)

Role: collaborator

All 6 trials loaded